Navigation Links
Journalist Petitions Court Pleading Mercy Killing

A 79-year-old freelance journalist here has petitioned the Rajasthan High Court seeking permission for euthanasia, saying he wants to die with dignity//.

In his petition filed Wednesday, Giriraj Prasad Gupta pleaded for mercy killing on the ground that he was unable to perform his day-to-day functions independently and did not want to lead a crippled life waiting for death.

He said he had a hearing problem, diabetes, poor vision and heart disorders. He has been operated upon for hernia and prostate, and he had fractured his legs and hands once. He said he wanted to "die with dignity" rather than become a bedridden patient waiting for death.

The journalist clarified that he was loved and taken care of by his family members, who were all well settled. He also said that he was able to earn Rs.8,000 a month.

Arguing that the Hindu scripture Bhagavad Gita and the Jain philosophy speak of immortality and reincarnation, Gupta said he wanted to facilitate transfer of his soul into a new body.

Gupta's counsel N.C. Goel said his client wanted to die with dignity, for which he would require a doctor's help and the doctor should also not be penalised for it.

--Edited IANS
'"/>




Page: 1

Related medicine news :

1. Journalists Blamed For Bird Flu Spread Across Israel
2. Journalist Alok Tomar arrested
3. Parke-Davis (India) runs into rough weather – Court orders attachment of asset
4. Bihar High Court Intervenes To End Doctors Strike
5. High Court Issues Notice To Centre On Smoking Ban In Films
6. Madras High Court Disapproves of Comparative Advertisements
7. Another British Woman In Court For New Breast Cancer Drug
8. Fizzy Logic For A Perfect Drink: Courtesy Boffins
9. Australian Court Finds Man Guilty of Spreading HIV/AIDS
10. Dare Not Mercy kill – Courtesy: The Care Not Killing Grou
11. Court Orders Private Hospitals To Provide Free Treatment For The Poor
Post Your Comments:
Other Medicine News:Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 1YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 3OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 1OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 2Fitness Might Limit Strokes Impact 51687 1Fitness Might Limit Strokes Impact 51687 2